Andy Hsieh
Stock Analyst at William Blair
(2.78)
# 1,963
Out of 5,090 analysts
13
Total ratings
71.43%
Success rate
17.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Upgrades: Outperform | n/a | $29.36 | - | 2 | Nov 3, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $10.24 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $1.20 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $5.24 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $34.56 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $11.61 | - | 1 | Feb 28, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $27.78 | - | 1 | Feb 6, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $4.22 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $63.30 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $8.42 | - | 2 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.43 | - | 1 | Feb 21, 2023 |
Terns Pharmaceuticals
Nov 3, 2025
Upgrades: Outperform
Price Target: n/a
Current: $29.36
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $10.24
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $5.24
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $34.56
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $11.61
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $27.78
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.22
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $63.30
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.42
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.43
Upside: -